ArticleAnnals of hematology2026
Burden of disease for multiple myeloma in China and the Asia-Pacific region, 1990-2021: a systematic analysis of the Global Burden of Disease (GBD) 2021 study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This project tracks Asia-Pacific multiple myeloma (MM) disease burden from 1990 to 2021. This research predicts incidence and death trends due to aging populations, healthcare resource disparities, gender, regional differences, and health inequities. The 2021 Global Burden of Disease (GBD) database was used to extract Asia-Pacific MM incidence, mortality, and Disability Adjusted Life Year (DALY) by age and sex from 1990 to 2021. Joinpoint regression studied temporal patterns, while APC models deconstructed drivers. The slope inequality index (SII) and concentration index (CI) measured health inequalities, whereas decomposition analysis measured aging, population growth, and epidemiological transition. Predictions using Autoregressive Integrated Moving Average(ARIMA) and Bayesian Age-Period-Cohort(BAPC). Between 1990 and 2021, the worldwide burden of MM grew, particularly in China, where age-standardized incidence reached 918.69%, death 326%, and DALY 622.15%. Approximately 60% of East Asia's increase was due to population aging. Males were more affected than females, with most occurrences occurring in those over 70. Early diagnosis was common in low-income communities. MM prevalence correlated positively with Socio-demographic Index (SDI) except in Japan, where it varied negatively. Disease incidence is predicted to rise in China, while fatality rates should steady. Additionally, male disease burden is expected to continue higher than female disease burden throughout time. MM incidence, mortality, and DALY have increased globally and in the Asia-Pacific area. China's disease burden is male-dominated, age-driven, and positively correlated with SDI. Future incidence rates are predicted to climb, especially among the elderly and males, requiring differentiated prevention and control efforts. Innovative global tactics may come from the Japanese model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.